Recursion Pharmaceuticals is trading 10.36% up at $3.41, mainly as biotech stocks rallied after positive Phase 3 melanoma cancer-vaccine results from Moderna and Merck.
- No clear company-specific announcement was identified for August 19, 2026.
- The results lifted optimism around biotechnology and mRNA drug development.
- Recursion’s recent pipeline and cost updates may support sentiment, but they predate today’s move.